High Incidence of Cytomegalovirus Disease in D+/R- Heart Transplant Recipients Shortly After Completion of 3 Months of Valganciclovir Prophylaxis

Journal of Heart and Lung Transplantation

Volumn 27, Issue 5, 2008, Pages 536-539

  Gupta, Sachin ^a   Mitchell, Joshua D ^a   Markham, David W ^a   Mammen, Pradeep P A ^a   Patel, Parag C ^a   Kaiser, Patricia ^b   Ring, W Steves ^a   DiMaio, J Michael ^a   Drazner, Mark H ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CYCLOSPORIN; GANCICLOVIR; HYPERIMMUNE GLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; VALGANCICLOVIR;

ARTICLE; CLINICAL ARTICLE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG WITHDRAWAL; GRAFT RECIPIENT; HEART GRAFT; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; PRIORITY JOURNAL; PROPHYLAXIS; RETROSPECTIVE STUDY; TREATMENT DURATION;

ADULT; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; HEART TRANSPLANTATION; HUMANS; IMMUNOGLOBULINS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 42649127721     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2008.02.002     Document Type: Article

References (14)

1. Valantine H.A., Gao S.Z., Menon S.G., et al. Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study. Circulation 100 (1999) 61-66
2. Hart G.D., and Paya C.V. Prophylaxis for CMV should now replace pre-emptive therapy in solid organ transplantation. Rev Med Virol 11 (2001) 73-81
3. Singh N. Delayed occurrence of cytomegalovirus disease in organ transplant recipients receiving antiviral prophylaxis: are we winning the battle only to lose the war?. Eur J Clin Microbiol Infect Dis 21 (2002) 643-646
4. Devyatko E., Zuckermann A., Ruzicka M., et al. Pre-emptive treatment with oral valganciclovir in management of CMV infection after cardiac transplantation. J Heart Lung Transplant 23 (2004) 1277-1282
5. Vrtovec B., Thomas C.D., Radovancevic R., Frazier O.H., and Radovancevic B. Comparison of intravenous ganciclovir and cytomegalovirus hyperimmune globulin pre-emptive treatment in cytomegalovirus-positive heart transplant recipients. J Heart Lung Transplant 23 (2004) 461-465
6. Zamora M.R., Nicolls M.R., Hodges T.N., et al. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am J Transplant 4 (2004) 1635-1642
7. Doyle A.M., Warburton K.M., Goral S., et al. 24-week oral ganciclovir prophylaxis in kidney recipients is associated with reduced symptomatic cytomegalovirus disease compared to a 12-week course. Transplantation 81 (2006) 1106-1111
8. Preiksaitis J.K., Brennan D.C., Fishman J., and Allen U. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 5 (2005) 218-227
9. Rosenberg P.B., Vriesendorp A.E., Drazner M.H., et al. Induction therapy with basiliximab allows delayed initiation of cyclosporine and preserves renal function after cardiac transplantation. J Heart Lung Transplant 24 (2005) 1327-1331
10. Potena L., Holweg C.T., Chin C., et al. Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection. Transplantation 82 (2006) 398-405
11. Potena L., Holweg C.T., Vana M.L., et al. Frequent occult infection with cytomegalovirus in cardiac transplant recipients despite antiviral prophylaxis. J Clin Microbiol 45 (2007) 1804-1810
12. Kijpittayarit-Arthurs S., Eid A.J., Kremers W.K., et al. Clinical features and outcomes of delayed-onset primary cytomegalovirus disease in cardiac transplant recipients. J Heart Lung Transplant 26 (2007) 1019-1024
13. Carrier M., Leblanc M.H., Perrault L.P., et al. Basiliximab and rabbit anti-thymocyte globulin for prophylaxis of acute rejection after heart transplantation: a non-inferiority trial. J Heart Lung Transplant 26 (2007) 258-263
14. Boucher A., Lord H., Collette S., Morin M., and Dandavino R. Cytomegalovirus infection in kidney transplant recipients: evolution of approach through three eras. Transplant Proc 38 (2006) 3506-3508